The blockage of S100a9-mediated pathways by these drugs leads to several immune modulatory and tumor microenvironment impairing effects; the reduced production of the key pro-inflammatory cytokines and chemokines for immune cell activation and recruitment to inflammation or tumor growth sites88, anti-angiogenic effects (caused by Tasquinimod)87, and the diminished myeloid-derived suppressor cells and tumor-associated macrophages, which can suppress the development and metastasis of tumor88,89. Here, S100A9 is linked to neoplasm.